

Seeking Novel Therapies for the Treatment of Skin Disorders

LEO Pharma, a global leader in medical dermatology, headquartered in Copenhagen, Denmark, is seeking new partnering or in-licensing opportunities within **medical dermatology**. Specifically, the team is interested in **novel opportunities that modulate immuno-inflammatory targets/pathways** with rationale for rare or common skin disorders, including but not limited to the treatment of eczema, epidermolysis bullosa, bullous pemphigoid, rosacea, hidradenitis suppurativa, alopecia areata, vitiligo and melasma.



Approaches of Interest:

- LEO Pharma is **open to different modalities** including small molecules, biologics, mRNA therapeutics or gene therapy approaches
- All potential routes of administration are of interest, with a **preference for topical or oral delivery**
- Drug repurposing/repositioning and therapeutics used to target mechanisms and pathways related to diseases of other tissues (e.g. asthma), which have potential to be applied to treatment of skin disorders are of interest

Out of Scope:

- Skin cancer / melanoma and infectious skin disorders
- Aesthetic or cosmetic products and opportunities related to scarring and wound healing
- Stem cells / stem cell therapy
- Opportunities related to drug screening approaches

Developmental Stages of Interest:

- Opportunities from basic research phase to Phase III stage are within scope
- For opportunities in preclinical stages, evidence of efficacy (*in vitro* or *in vivo*), is preferred


Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities to **Karla Schramm** at kschramm.usf.edu

Deadline: 31st May 2024- 5:00 pm GMT

Have any questions?

Contact **Karla Schramm** at kschramm.usf.edu



LEO Pharma, a global leader in medical dermatology, is dedicated to advancing the standard of care for the benefit of people with skin conditions. The company has a presence in more than 88 markets and serves more than 95 million patients across the world.